|
1.
|
V AmbrosThe functions of animal
microRNAsNature431350355200410.1038/nature0287115372042
|
|
2.
|
VN KimJ-W NamGenomics of microRNATrends
Genet22165173200610.1016/j.tig.2006.01.00316446010
|
|
3.
|
AJ SchetterNHH HeegaardCC
HarrisInflammation and cancer: interweaving microRNA, free radical,
cytokine and p53
pathwaysCarcinogenesis313749201010.1093/carcin/bgp27219955394
|
|
4.
|
PB KwakS IwasakiY TomariThe microRNA
pathway and cancerCancer
Sci10123092315201010.1111/j.1349-7006.2010.01683.x20726859
|
|
5.
|
S VoliniaGA CalinC-G LiuA microRNA
expression signature of human solid tumors defines cancer gene
targetsProc Natl Acad Sci
USA10322572261200610.1073/pnas.051056510316461460
|
|
6.
|
N YanaiharaN CaplenE BowmanUnique microRNA
molecular profiles in lung cancer diagnosis and prognosisCancer
Cell9189198200610.1016/j.ccr.2006.01.02516530703
|
|
7.
|
J-W SonY-J KimH-M ChoMicroRNA expression
profiles in Korean non-small cell lungTuberc Respir
Dis67413421200910.4046/trd.2009.67.5.413
|
|
8.
|
AM ChengMW ByromJ SheltonLP FordAntisense
inhibition of human miRNAs and indications for an involvement of
miRNA in cell growth and apoptosisNucleic Acids
Res3312901297200510.1093/nar/gki20015741182
|
|
9.
|
C-Z ChenL LiHF LodishDP BartelMicroRNAs
modulate hematopoietic lineage
differentiationScience3038386200410.1126/science.109190314657504
|
|
10.
|
A Esquela-KerscherP TrangJF WigginsThe
let-7 microRNA reduces tumor growth in mouse models of lung
cancerCell Cycle7759764200810.4161/cc.7.6.583418344688
|
|
11.
|
L MaJ YoungH PrabhalamiR-9, a
MYC/MYCN-activated microRNA, regulates E-cadherin and cancer
metastasisNat Cell Biol12247256201020173740
|
|
12.
|
BP LewisCB BurgeDP BartelConserved seed
pairing, often flanked by adenosines, indicates that thousands of
human genes are microRNA
targetsCell1201520200510.1016/j.cell.2004.12.03515652477
|
|
13.
|
FR LamontDC TomlinsonPA CooperSD ShnyderJD
ChesterMA KnowlesSmall molecule FGF receptor inhibitors block
FGFR-dependent urothelial carcinoma growth in vitro and in vivoBr J
Cancer1047582201110.1038/sj.bjc.660601621119661
|
|
14.
|
DM OrnitzJ XuJS ColvinReceptor specificity
of the fibroblast growth factor familyJ Biol
Chem2711529215297199610.1074/jbc.271.25.152928663044
|
|
15.
|
EM HaugstenA WiedlochaS OlsnesJ
WescheRoles of fibroblast growth factor receptors in
carcinogenesisMol Cancer
Res814391452201010.1158/1541-7786.MCR-10-016821047773
|
|
16.
|
D HanahanRA WeinbergThe hallmarks of
cancerCell1005770200010.1016/S0092-8674(00)81683-9
|
|
17.
|
RJ WebsterKM GilesKJ PricePM ZhangJS
MattickPJ LeedmanRegulation of epidermal growth factor receptor
signaling in human cancer cells by microRNA-7J Biol
Chem28457315741200910.1074/jbc.M80428020019073608
|
|
18.
|
WC ChoAS ChowJS AuMiR-145 inhibits cell
proliferation of human lung adenocarcinoma by targeting EGFR and
NUDT1RNA Biol8125131201110.4161/rna.8.1.14259
|
|
19.
|
M GarofaloG Di LevaG RomanomiR-221&222
regulate TRAIL resistance and enhance tumorigenicity through PTEN
and TIMP3 downregulationCancer Cell164985092009
|
|
20.
|
MW NasserJ DattaG NuovoDown-regulation of
micro-RNA-1 (miR-1) in lung cancerJ Biol
Chem2833339433405200818818206
|
|
21.
|
C BillereyD ChopinM-H
Aubriot-LortonFrequent FGFR3 mutations in papillary non-invasive
bladder (pTa) tumorsAm J
Pathol15819551959200110.1016/S0002-9440(10)64665-211395371
|
|
22.
|
D CappellenC De OliveiraD RicolFrequent
activating mutations of FGFR3 in human bladder and cervix
carcinomasNat Genet231820199910.1038/1261510471491
|
|
23.
|
S KangS DongT-L GuFGFR3 activates RSK2 to
mediate hematopoietic transformation through tyrosine
phosphorylation of RSK2 and activation of the MEK/ERK pathwayCancer
Cell12201214200710.1016/j.ccr.2007.08.00317785202
|
|
24.
|
L ChengS ZhangDD DavidsonMolecular
determinants of tumor recurrence in the urinary bladderFuture
Oncol5843857200910.2217/fon.09.5019663734
|
|
25.
|
M ChesiE NardiniLA BrentsFrequent
translocation t(4;14)(p16.3;q32.3) in multiple myeloma is
associated with increased expression and activating mutations of
fibroblast growth factor receptor 3Nat
Genet16260264199710.1038/ng0797-2609207791
|
|
26.
|
DC TomlinsonO BaldoP HarndenMA
KnowlesFGFR3 protein expression and its relationship to mutation
status and prognostic variables in bladder cancerJ
Pathol2139198200710.1002/path.220717668422
|
|
27.
|
M KarouiH Hofmann-RadvanyiU ZimmermannNo
evidence of somatic FGFR3 mutation in various types of
carcinomaOncogene2050595061200110.1038/sj.onc.120465111526491
|
|
28.
|
M WoenckhausJ MerkR StoehrPrognostic value
of FHIT, CTNNB1, and MUC1 expression in non-small cell lung
cancerHum
Pathol39126136200810.1016/j.humpath.2007.05.02717949785
|
|
29.
|
S ThomsonF PettiI Sujka-KwokD EpsteinJ
HaleyKinase switching in mesenchymal-like non-small cell lung
cancer lines contributes to EGFR inhibitor resistance through
pathway redundancyClin Exp
Metastasis25843854200810.1007/s10585-008-9200-418696232
|
|
30.
|
L MarekKE WareA FritzscheFibroblast growth
factor (FGF) and FGF receptor-mediated autocrine signaling in
non-small-cell lung cancer cellsMol
Pharmacol75196207200910.1124/mol.108.04954418849352
|
|
31.
|
SA KonoME MarshallKE WareLE HeasleyThe
fibroblast growth factor receptor signaling pathway as a mediator
of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors
in non-small cell lung cancerDrug Resist
Updat1295102200910.1016/j.drup.2009.05.00119501013
|
|
32.
|
M IwatsukiK MimoriT
YokoboriEpithelial-mesenchymal transition in cancer development and
its clinical significanceCancer
Sci101293299201010.1111/j.1349-7006.2009.01419.x19961486
|
